Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells 58,014 Shares of Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 58,014 shares of the stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $51.81, for a total value of $3,005,705.34. Following the transaction, the chief executive officer owned 64,944 shares of the company’s stock, valued at $3,364,748.64. The trade was a 47.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total value of $732,178.08.
• On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.38, for a total transaction of $5,362,535.96.
• On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.15, for a total transaction of $144,848.00.
• On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.47, for a total transaction of $400,600.20.
• On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $268,322.37.
• On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.12, for a total transaction of $271,692.64.
• On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.55, for a total value of $50,079.25.
• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.98, for a total value of $552,372.84.
• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.68, for a total value of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.02, for a total value of $117,338.64.

Phibro Animal Health Price Performance

Shares of PAHC traded down $0.22 during midday trading on Wednesday, hitting $51.52. 352,907 shares of the company traded hands, compared to its average volume of 265,479. Phibro Animal Health Corporation has a one year low of $16.16 and a one year high of $56.30. The firm has a market cap of $2.09 billion, a P/E ratio of 22.90, a PEG ratio of 0.80 and a beta of 0.80. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. The stock has a 50-day moving average of $40.54 and a 200-day moving average of $38.75.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. The company had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, sell-side analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. Phibro Animal Health’s dividend payout ratio is presently 21.33%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a research note on Friday, February 6th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. JPMorgan Chase & Co. upped their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Finally, Zacks Research cut Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Monday. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $37.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PAHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Phibro Animal Health by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after purchasing an additional 546 shares during the period. Millennium Management LLC grew its position in shares of Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after buying an additional 154,281 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Phibro Animal Health by 65.3% during the first quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock valued at $724,000 after buying an additional 13,404 shares during the period. Yousif Capital Management LLC bought a new position in shares of Phibro Animal Health during the second quarter valued at approximately $200,000. Finally, Envestnet Asset Management Inc. lifted its stake in Phibro Animal Health by 97.3% in the second quarter. Envestnet Asset Management Inc. now owns 24,334 shares of the company’s stock worth $621,000 after acquiring an additional 11,999 shares during the period. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.